Moreover, a 10-year follow-up of two patients with chronic lymphocytic leukemia who achieved remission after treatment with CD19 CAR-T cells uncovered that the engineered population still present at later time points was dominated by CD4 T lymphocytes. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.